Atavistik was founded by prominent scientists who are considered among the leading authorities in cell biology, cancer cell biology and cell metabolism.

In August 2021, the US company completed a $60 million Series A financing round. This will support development of Atavastik’s drug discovery platform, and future identification of select drug candidates based on deep knowledge of disease relevant pathways that have evolved over millions of years by nature to be allosterically regulated by metabolites.